Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2NUH3)

• Drug Name: Imipramine Drug Info
• Synonyms: Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Nocturia	MF55	Approved	[2]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 3696
  ChEBI ID: CHEBI:47499
  CAS Number: CAS 50-49-7
  TTD Drug ID: DM2NUH3
  VARIDT Drug ID: DR00552
  INTEDE Drug ID: DR0861
  ACDINA Drug ID: D00325

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[19]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[20]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[19]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[21]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[22]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[23]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[22]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[24]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[25]
Levomilnacipran	DMV26S8	Fibromyalgia	MG30.01	Approved	[26]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[29]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[30]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[33]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[34]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[35]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[36]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[39]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[40]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[35]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[42]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[43]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[44]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[46]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[47]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[40]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[49]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[50]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[51]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[52]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[54]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[55]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[56]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[57]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[58]
Metronidazole	DMTIVEN	Abscess		Approved	[59]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[60]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[61]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[62]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[63]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[42]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[65]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[66]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[67]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[68]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[69]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[70]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[71]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[71]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[71]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[72]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[73]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[71]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[71]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[71]
Metronidazole	DMTIVEN	Abscess		Approved	[74]

Drug(s) Metabolized By Cytochrome P450 2C18 (CYP2C18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[72]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[75]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[76]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[72]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[78]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[79]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[80]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[72]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[81]

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[82]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[72]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[83]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[86]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[87]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[88]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[89]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[90]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[91]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[92]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[94]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[72]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[95]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[96]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[97]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[76]

Drug(s) Metabolized By Docosahexaenoic acid omega-hydroxylase (CYP4F11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[11]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[11]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[11]
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[11]

Drug(s) Affected By Glutathione S-transferase P (GSTP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[98]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[100]
Chlorambucil	DMRKE63	Chronic lymphocytic leukaemia	2A82.0	Approved	[100]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[101]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[102]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Selenium	DM25CGV	N. A.	N. A.	Approved	[104]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[105]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[106]

Drug(s) Affected By Nuclear protein 1 (NUPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[107]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[108]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[111]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[108]

Drug(s) Affected By Alpha-1-antichymotrypsin (SERPINA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[113]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[114]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[115]

Drug(s) Affected By Serine protease hepsin (HPN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Selenium	DM25CGV	N. A.	N. A.	Approved	[104]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]

Drug(s) Affected By Fatty acid-binding protein, liver (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[120]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[121]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]

Drug(s) Affected By Asparagine synthetase (ASNS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[122]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[123]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[124]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[108]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[126]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[125]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[128]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[102]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[129]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[131]

Drug(s) Affected By Lanosterol synthase (LSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[132]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[133]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[134]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[13]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]

Drug(s) Affected By Inhibin beta E chain (INHBE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[134]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[13]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[135]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[108]

Drug(s) Affected By Transgelin (TAGLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[136]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[137]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[138]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[109]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[139]

Drug(s) Affected By Acid ceramidase (ASAH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[140]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[108]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[141]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[108]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[13]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[143]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[144]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[145]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[132]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[108]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[146]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[147]

Drug(s) Affected By Lysophospholipase D GDPD3 (GDPD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[109]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[108]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[108]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[148]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[149]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[149]
Haloperidol	DM96SE0	Delirium		Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[150]

Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]
Haloperidol	DM96SE0	Delirium		Approved	[108]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[13]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[13]

Drug(s) Affected By Protein DEPP1 (DEPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[13]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[108]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[151]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[152]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[108]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[108]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]

Drug(s) Affected By Acetylcholinesterase (ACHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[153]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[154]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[129]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[155]
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[154]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[156]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[157]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[158]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[159]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]

Drug(s) Affected By Stearoyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[132]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[160]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[120]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[113]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[160]
Fructose	DM43AN2	Vomiting	MD90	Approved	[161]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[162]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[163]

Drug(s) Affected By Transmembrane protease serine 2 (TMPRSS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[16]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[16]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Selenium	DM25CGV	N. A.	N. A.	Approved	[104]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[16]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[16]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[16]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[16]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[164]

Drug(s) Affected By Albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[165]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[166]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[167]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[168]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[169]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[170]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[171]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[172]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[173]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[133]

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[174]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[175]
Terbutaline	DMD4381	Asthma	CA23	Approved	[176]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[177]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[129]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[178]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[152]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[179]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[180]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[181]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[107]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[183]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[184]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[185]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[186]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[187]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[188]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[189]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[190]

Drug(s) Affected By Alpha-1-acid glycoprotein 2 (ORM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[135]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[15]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[15]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[149]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[149]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[191]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[192]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[193]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[194]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[195]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[196]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[197]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[199]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[200]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[201]

Drug(s) Affected By Caspase-7 (CASP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[202]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[203]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[204]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[205]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[18]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[206]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[207]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[208]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[209]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[210]

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[212]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[213]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[214]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[212]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[212]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[212]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[212]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[213]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[215]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[216]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[217]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[160]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[133]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[134]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[162]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[218]

Drug(s) Affected By Glutamate receptor ionotropic, NMDA 1 (GRIN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[219]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[220]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[219]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[159]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[221]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[219]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[222]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[223]
Sulfadiazine	DMTW3R8	Rheumatic fever	1B40-1B42	Approved	[219]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[219]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[224]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[225]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[226]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[227]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[227]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[228]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[229]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[230]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[231]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[227]

Drug(s) Affected By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[232]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[233]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[234]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[120]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[235]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[236]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[237]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[233]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[238]

Drug(s) Affected By Angiotensin-converting enzyme 2 (ACE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Captopril	DM458UM	Chronic heart failure	BD1Z	Approved	[239]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[16]
Dantrolene	DM1D8XY	Hyperthermia	MG26	Approved	[16]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[16]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[16]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[16]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[16]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[16]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[16]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[16]

Drug(s) Affected By DnaJ homolog subfamily C member 5 (DNAJC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[240]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[241]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[242]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[243]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[244]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[245]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[242]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[246]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[247]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[247]

Drug(s) Affected By SH3 and multiple ankyrin repeat domains protein 2 (SHANK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Selenium	DM25CGV	N. A.	N. A.	Approved	[104]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[219]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[219]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[117]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[118]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[248]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[249]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[99]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[6]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[9]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[9]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[10]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[9]
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DEIZLTN	CP4FB_HUMAN	Substrate	[11]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[12]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[13]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[14]
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[15]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[13]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[16]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[13]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Gene/Protein Processing	[17]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[18]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[18]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 357).
• [2] Imipramine FDA Label
• [3] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [4] Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
• [5] Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
• [6] QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
• [7] Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
• [8] Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
• [9] Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
• [10] Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos. 1999 Nov;27(11):1306-8.
• [11] Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
• [12] Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
• [13] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [14] Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
• [15] Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
• [16] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [17] Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
• [18] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [19] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [20] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [21] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [22] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [23] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [24] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [25] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [26] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [27] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [28] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [29] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [30] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [31] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [32] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [33] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [34] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [35] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [36] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [37] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [38] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [39] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [40] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [41] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [42] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [43] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [44] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [45] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [46] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [47] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [48] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [49] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [50] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [51] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [52] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [53] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [54] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [55] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [56] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [57] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [58] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [59] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [60] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [61] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [62] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [63] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [64] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [65] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [66] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [67] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [68] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [69] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [70] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [71] Drug Interactions Flockhart Table
• [72] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [73] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [74] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [75] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [76] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [77] Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
• [78] Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
• [79] Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
• [80] CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
• [81] Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
• [82] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [83] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [84] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [85] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [86] Drugs that may have potential CYP2B6 interactions.
• [87] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [88] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [89] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [90] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [91] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [92] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [93] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [94] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [95] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [96] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [97] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [98] Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.
• [99] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [100] The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug;294(2):480-7.
• [101] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [102] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [103] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [104] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [105] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [106] Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol In Vitro. 2011 Apr;25(3):671-83.
• [107] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [108] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [109] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [110] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [111] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [112] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [113] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [114] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [115] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [116] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [117] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [118] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [119] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [120] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [121] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [122] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [123] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [124] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [125] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [126] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [127] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [128] Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
• [129] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [130] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [131] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [132] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [133] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [134] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [135] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [136] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [137] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [138] Differentiation of human embryonic stem cells into smooth muscle cells in adherent monolayer culture. Biochem Biophys Res Commun. 2006 Dec 15;351(2):321-7. doi: 10.1016/j.bbrc.2006.09.171. Epub 2006 Oct 17.
• [139] Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther. 2007 Jan;6(1):70-81. doi: 10.1158/1535-7163.MCT-06-0125.
• [140] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [141] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [142] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [143] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [144] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [145] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [146] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [147] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [148] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [149] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [150] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [151] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [152] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [153] Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. Chem Biol Interact. 2008 Sep 25;175(1-3):235-41. doi: 10.1016/j.cbi.2008.06.002. Epub 2008 Jun 17.
• [154] Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
• [155] Tribromophenol induces the differentiation of SH-SY5Y human neuroblastoma cells in vitro. Toxicol In Vitro. 2003 Oct-Dec;17(5-6):635-41. doi: 10.1016/s0887-2333(03)00110-3.
• [156] Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol. 1989 Nov 28;173(1):53-64. doi: 10.1016/0014-2999(89)90008-3.
• [157] Interaction of dichlorvos and anticholinesterases on the in vitro inhibition of human blood cholinesterases. Toxicol Appl Pharmacol. 1974 Feb;27(2):456-63.
• [158] Hairy-root organ cultures for the production of human acetylcholinesterase. BMC Biotechnol. 2008 Dec 23;8:95.
• [159] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [160] Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
• [161] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [162] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [163] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [164] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [165] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [166] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [167] A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
• [168] The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
• [169] Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
• [170] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [171] [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
• [172] Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
• [173] Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
• [174] Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
• [175] Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
• [176] Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
• [177] beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
• [178] Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
• [179] Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
• [180] Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
• [181] Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004 Dec 16;4:93. doi: 10.1186/1471-2407-4-93.
• [182] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [183] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [184] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [185] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [186] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [187] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [188] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [189] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [190] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [191] Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver Int. 2008 Aug;28(7):997-1010. doi: 10.1111/j.1478-3231.2008.01744.x. Epub 2008 Apr 15.
• [192] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [193] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [194] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [195] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [196] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [197] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [198] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [199] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [200] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [201] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [202] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [203] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [204] A model to identify novel targets involved in oxidative stress-induced apoptosis in human lung epithelial cells by RNA interference. Toxicol In Vitro. 2010 Feb;24(1):310-8. doi: 10.1016/j.tiv.2009.08.008. Epub 2009 Aug 23.
• [205] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [206] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [207] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [208] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [209] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [210] Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
• [211] NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
• [212] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [213] Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
• [214] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [215] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [216] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [217] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [218] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [219] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [220] All-trans-retinoic acid induces manganese superoxide dismutase in human neuroblastoma through NF-kappaB. Free Radic Biol Med. 2008 Apr 15;44(8):1610-6. doi: 10.1016/j.freeradbiomed.2008.01.015. Epub 2008 Jan 30.
• [221] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [222] Cocaine-induced alterations in nucleus accumbens ionotropic glutamate receptor subunits in human and non-human primates. J Neurochem. 2005 Dec;95(6):1785-93. doi: 10.1111/j.1471-4159.2005.03517.x.
• [223] Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
• [224] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [225] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [226] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [227] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [228] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [229] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [230] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [231] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [232] Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097. doi: 10.1016/j.cbi.2020.109097. Epub 2020 Apr 16.
• [233] Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006 Nov;34(11):1868-74. doi: 10.1124/dmd.106.010876. Epub 2006 Aug 23.
• [234] Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
• [235] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [236] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [237] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [238] Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicol In Vitro. 2017 Sep;43:87-91. doi: 10.1016/j.tiv.2017.06.007. Epub 2017 Jun 9.
• [239] Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. doi: 10.1038/sj.clpt.6100214. Epub 2007 May 2.
• [240] Induction of cysteine string protein after chronic antidepressant treatment in rat frontal cortex. Neurosci Lett. 2001 Apr 6;301(3):183-6. doi: 10.1016/s0304-3940(01)01638-x.
• [241] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [242] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [243] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [244] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [245] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [246] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [247] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [248] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [249] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.